panthenol

Small moleculeapproved

Approved

Jul 28, 1947

Panthenol (pantothenol) is an alcohol form of the B5 vitamin pantothenic acid. It easily penetrates the skin retaining water and is a humectant, emollient and moisturizer. Panthenol mitigates signs of inflammation and stimulates epithelization. Panthenol comes in two enantiomers, D and L. Only D-panthenol (dexpanthenol) is biologically active, however both forms have moisturizing properties. Because of the ability to attract and hold moisture panthenol is used in skincare products as a humectant. It also has a role as provitamin (called pro-vitamin B5) and is used as a vitamin supplement in complex ( M.V.I. ADULT injection, Hospira Worldwide, Inc.) and alone, and as a cholinergic drug. Panthenol is a highly viscous transparent liquid at room temperature, but salts of pantothenic acid (sodium pantothenate) are powders (typically white). It is soluble in water, alcohol, propylene glycol, ether and chloroform, and slightly soluble in glycerin. Panthenol mixes readily with many different types of ingredients, making it a versatile ingredient to be used in formulas because it improves skin’s barrier function and maintains the proliferation of fibroblasts. In organisms it is quickly oxidized to pantothenate (pantothenic acid). Defficiency of Vitamin B5 results in many dermatological disorder. Due to the fact that only D-Panthenol is converted to Vitamin B5 and not L-Panthenol, the racemic mixture of D- and L- panthenol (DL-panthenol) has only half of the physiological activity of the D-Panthenol. These include stimulation of epithelisation, wound healing effect and anti-infl ammatory effect. Panthenol is FDA approved for cosmetic use and comes either in D form, or as a racemic mixture. It is also in the FDA list of over-the-counter drug products that are not generally recognized as safe and effective or are misbranded: as "Insect Bite and Sting Drug Products" and "Poison Ivy, Poison Oak, and Poison Sumac Drug Products". — NCATS

Clinical trial activity

24 trials · 28 clinical orgs · 8 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Aug 1, 2007 (NCT00839280)

Timeline

1940s

Jul 28, 1947
Roche — Earliest FDA Approval
Jul 28, 1947
Roche — NDA Secondary Org
Jul 28, 1947
Roche — NDA Organization

1950s

Feb 20, 1953
Hospira — NDA Secondary Org

1980s

Nov 6, 1981
Abraxis — NDA Secondary Org
Jul 13, 1982
Watson Pharmaceuticals — NDA Secondary Org

2000s

May 18, 2000
Sandoz — NDA Secondary Org
May 18, 2000
Novartis — NDA Secondary Org
Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Jan 1, 2008
Roche — Earliest Phase 3 Sponsor(trial)
Jan 1, 2009
Earliest Phase 1 Sponsor(trial)

2020s

Apr 9, 2026
Apotex — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Pantothenate kinaseBINDING AGENT
coaA binding agent
- Pantothenate kinase (coaA) ↗

Combination products

berocca pn
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, biotin, pyridoxine, riboflavin, vitamin a, ergocalciferol
Also known as m.v.c, mvc plus
infuvite
with vitamin d3, vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, vitamin k, biotin, pyridoxine, riboflavin, vitamin a
Also known as infuvite pediatric, infuvite pediatric (pharmacy bulk package)
m.v.i. adult (pharmacy bulk package)
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, vitamin k, biotin, pyridoxine, riboflavin, vitamin a, ergocalciferol
m.v.i. pediatric
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, biotin, pyridoxine, riboflavin, vitamin a, phytonadione, ergocalciferol

Approval history

approvedJul 28, 1947

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(CO)C(O)C(=O)NCCCO

Mol. weight: 205.2515 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Prescription Only

Oral

Parenteral

Yes

Topical

Sources

Also known as

2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide
2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide
(+)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutyramide
(2r)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide
(2r)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide
bepanthen
bepanthen
bepanthen
bepanthen
bepanthene
bepanthene
bepantol
bepantol
butanamide, 2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethyl-, (+--)-
corneregel
cozyme
cozyme
d-(+)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutyramide
d-(+)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutyramide
dexpantenol
dexpantenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol
dexpanthenol heumann
dl-panthenol
d-panthenol
d-panthenol
d-panthenol
d-panthenol
d-panthenol
d(+)-panthenol
d(+)-panthenol
d-panthenol 50
d-panthenol 50
d-panthenol 50
d-pantothenol
d-pantothenol
d-pantothenyl alcohol
d-pantothenyl alcohol
d-pantothenyl alcohol
d(+)-pantothenyl alcohol
d(+)-pantothenyl alcohol
ilopan
ilopan
ilopan
ilopan
marolderm
motilyn
motilyn
motilyn
nasenspray ratiopharm panthenol
nasicur
n-pantoyl-propanolamine
n-pantoyl-propanolamine
otriven dexpanthenol
panadon
panadon
pan-ophtal
pan rhinol
panthenol
panthenol
panthenol
panthenol
panthenol
(+)-panthenol
(+)-panthenol
(+)-panthenol
(+)-panthenol
panthenol braun
panthenol jenapharm
panthenol law
panthenol lichtenstein
panthenol-ratiopharm
panthenol von ct
panthoderm
panthogenat
pantol
pantol
pantothenol
pantothenol
pantothenol
pantothenol
pantothenyl alcohol
pantothenyl alcohol
pantothenyl alcohol
provitamin b
provitamin b
(r)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide
(r)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide
repa-ophtal
rhinoclir
royal jelly
sinecort
sinecort
siozwo sana
synapan
synapan
thenalton
thenalton
ucee d
urupan
wund- und heilsalbe law
zentinic
zentinic

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT07022288	N/A	Apr 20, 2025	Government of China, Shanghai China-Norm Management Consulting co.,LTD
NCT06822608	Phase 4	Feb 28, 2025	University of Athens
NCT05937529	N/A	Sep 27, 2023	L'Oreal, University of Copenhagen
NCT05588973	N/A	Dec 31, 2022	Cyprus University of Technology, German Oncology Center, Cyprus
NCT07002632	N/A	Jul 20, 2021	Gaziosmanpasa University
NCT04219358	Phase 2/Phase 3 (Phase 3)	Mar 23, 2019	Federal University of Health Science of Porto Alegre, Federal University of Rio Grande do Sul
NCT03852563	N/A	Mar 18, 2019	Bayer
NCT03853525	Phase 4	Feb 11, 2019	Bayer
NCT03853512	Phase 4	Feb 11, 2019	Bayer
NCT03853538	Phase 4	Jan 28, 2019	Bayer
NCT03439436	Phase 3	Feb 26, 2018	I.M. Sechenov First Moscow State Medical University, Johnson and Johnson, Pavlov First Saint Petersburg State Medical University, Research Clinical Centre of the Russian Railways, JSC
NCT03421912	N/A	Feb 16, 2018	Centre Leon Berard
NCT03520348	Phase 1	Oct 4, 2017	Laboratorios Sophia S.A de C.V.
NCT01691209	N/A	Oct 1, 2013	Bayer
NCT01533220	Phase 3	Jun 1, 2013	EMS S/A
NCT02379468	Phase 3	Apr 1, 2013	Alexandria University, European Egyptian Pharmaceutical Industries
NCT01531517	Phase 3	Jul 1, 2011	Alexandria University, Cairo University, European Egyptian Pharmaceutical Industries
NCT01136005	Phase 3	Sep 30, 2010	Bayer, CB Boers ORG, Impaqtt Foundation, Leiden University, Memorial Sloan-Kettering Cancer Center, Waterland Hospital
NCT01318889	Phase 2	Sep 1, 2010	Shahid Beheshti University of Medical Sciences
NCT00980135	Phase 2	Nov 1, 2009	Bayer

Showing 20 of 24 trials

Page 1 / 2

Organizations

Research & Development (28)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Bayer	For profit	10	9	5	2007
Alexandria University	Academic/Hospital	2	0	1	2011
European Egyptian Pharmaceutical Industries	For profit	2	2	1	2011
Cairo University	Academic/Hospital	1	0	1	2011
CB Boers ORG	For profit	1	0	1	2010
Centre Leon Berard	Academic/Hospital	1	1	1	2018
Cyprus University of Technology	Academic/Hospital	1	1	1	2022
EMS S/A	For profit	1	1	1	2013
Federal University of Health Science of Porto Alegre	Academic/Hospital	1	1	1	2019
Federal University of Rio Grande do Sul	Academic/Hospital	1	0	1	2019
Gaziosmanpasa University	Academic/Hospital	1	1	1	2021
German Oncology Center, Cyprus	Academic/Hospital	1	0	1	2022
Government of China	Government	1	1	1	2025
Impaqtt Foundation	Academic/Hospital	1	1	1	2010
I.M. Sechenov First Moscow State Medical University	Academic/Hospital	1	0	1	2018
Johnson and Johnson	For profit	1	1	1	2018
Laboratorios Sophia S.A de C.V.	For profit	1	1	1	2017
Leiden University	Academic/Hospital	1	0	1	2010
L'Oreal	For profit	1	0	1	2023
Memorial Sloan-Kettering Cancer Center	Academic/Hospital	1	0	1	2010

28 organizations

Page 1 / 2

Marketing (9)

Organization	Org type	Relationship	Date
Abraxis	For profit	NDA2	Nov 6, 1981
Apotex	For profit	MKTG	Apr 9, 2026
Hospira	For profit	NDA2	Feb 20, 1953
Novartis	For profit	NDA2	May 18, 2000
Roche	For profit	NDA2	Jul 28, 1947
Roche	For profit	NDA	Jul 28, 1947
Sandoz	For profit	NDA2	May 18, 2000
Teligent Pharmaceuticals	For profit	NDA2	—
Watson Pharmaceuticals	For profit	NDA2	Jul 13, 1982